TECLens is a clinical-stage ophthalmic medical device company pioneering quantitative corneal cross-linking (qCXL™) and the CXLens® delivery system to reshape the cornea with patterned UV light and continuous biomechanical control. Its CXLens® device includes an on-board ultrasound sensor to ensure adherence to a pre-calculated treatment plan derived from a computational biomechanics model of each patient’s eye. The system has been successfully demonstrated in eyes with keratoconus and is being advanced into clinical studies for refractive correction, with a primary focus on presbyopia. TECLens positions qCXL™ as a comfortable, non-incisional alternative to traditional refractive surgery and aims to improve precision and accessibility in vision correction. Potential future applications noted by the company include pediatric progressive myopia, low-order adult myopia, hyperopia, and astigmatism. The company announced new financing to support ongoing clinical development of its technology.

Total raised

$9M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2025